Biosimilar medicine authorized by the European Commission
ACTIVE PRINCIPLE: eculizumab
INDICATION: paroxysmal hemoglobinuria
DATE: 19/04/2023
STATUS: Authorized
MORE INFORMATION
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
SUBSCRIBE
